These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 2419882)

  • 21. Lack of evidence for aromatase in human prostatic tissues: effects of 4-hydroxyandrostenedione and other inhibitors on androgen metabolism.
    Brodie AM; Son C; King DA; Meyer KM; Inkster SE
    Cancer Res; 1989 Dec; 49(23):6551-5. PubMed ID: 2479464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estrogen formation in human prostatic tissue from patients with and without benign prostatic hyperplasia.
    Stone NN; Fair WR; Fishman J
    Prostate; 1986; 9(4):311-8. PubMed ID: 2431401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Smooth muscle cell of the canine prostate in spontaneous benign hyperplasia, steroid induced hyperplasia and estrogen or tamoxifen treated dogs.
    Bruengger A; Bartsch G; Hollinger BE; Holly B; Rohr HP
    J Urol; 1983 Dec; 130(6):1208-10. PubMed ID: 6196492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacologically induced ultrastructural and immunohistochemical changes in the prostate of the castrated dog.
    Aumüller G; Habenicht UF; el Etreby MF
    Prostate; 1987; 11(3):211-8. PubMed ID: 2446297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aromatase and other inhibitors in breast and prostatic cancer.
    Brodie AM; Banks PK; Inkster SE; Son C; Koos RD
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1043-8. PubMed ID: 2285580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Androgen- and estrogen-receptor content in spontaneous and experimentally induced canine prostatic hyperplasia.
    Trachtenberg J; Hicks LL; Walsh PC
    J Clin Invest; 1980 May; 65(5):1051-9. PubMed ID: 6154062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Aromatase inhibitors in the medical treatment of benign prostatic hypertrophy].
    Tunn UW; Goldschmidt AJ
    J Urol (Paris); 1993; 99(6):307. PubMed ID: 7516374
    [No Abstract]   [Full Text] [Related]  

  • 28. [Physiopathological aspects of the treatment of benign prostatic hypertrophy. Role of prostatic stroma and estrogens].
    Solè-Balcells F
    J Urol (Paris); 1993; 99(6):303-6. PubMed ID: 7516373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogens and benign prostatic hyperplasia: rationale for therapy with aromatase inhibitors.
    Henderson D
    Ann Med; 1991 Aug; 23(3):201-3. PubMed ID: 1718322
    [No Abstract]   [Full Text] [Related]  

  • 30. Aromatization of androstenedione to estrogen by benign prostatic hyperplasia, prostate cancer and expressed prostatic secretions.
    Stone NN; Laudone VP; Fair WR; Fishman J
    Urol Res; 1987; 15(3):165-7. PubMed ID: 3629751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of canine basal cells in prostatic post natal development, induction of hyperplasia, sex hormone-stimulated growth; and the ductal origin of carcinoma.
    Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
    Prostate; 2001 May; 47(3):149-63. PubMed ID: 11351344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunocytochemical localization of estrogen receptors in spontaneous and experimentally induced canine benign prostatic hyperplasia.
    Schulze H; Barrack ER
    Prostate; 1987; 11(2):145-62. PubMed ID: 2444954
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma.
    Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
    Prostate; 2001 Aug; 48(3):210-24. PubMed ID: 11494337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selection of 19-(ethyldithio)-androst-4-ene-3,17-dione (ORG 30958): a potent aromatase inhibitor in vivo.
    Geelen JA; Deckers GH; van der Wardt JT; Loozen HJ; Tax LJ; Kloosterboer HJ
    J Steroid Biochem Mol Biol; 1991 Feb; 38(2):181-8. PubMed ID: 1825923
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phenotypic modulation of the canine prostate after long-term treatment with androgens and estrogens.
    Aumüller G; Funke PJ; Hahn A; Hoffbauer G; Tunn U; Neumann F
    Prostate; 1982; 3(4):361-73. PubMed ID: 6181496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 5 alpha-reductase activity in epithelium and stroma of prostates from intact and castrated dogs treated with androstenedione, the aromatase inhibitor 1-methyl-1,4-androstadiene-3,17-dione, and cyproterone acetate.
    Tunn S; Hochstrate H; Habenicht UF; Krieg M
    Prostate; 1988; 12(3):243-53. PubMed ID: 2967468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-androgen effects of the aromatase inhibitor, atamestane.
    Shao TC; Marcelli M; Kong A; Cunningham GR
    J Androl; 1995; 16(2):100-7. PubMed ID: 7559139
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of peripheral aromatization by aromatase inhibitors, 4-hydroxy- and 4-acetoxy-androstene-3,17-dione.
    Brodie AM; Longcope C
    Endocrinology; 1980 Jan; 106(1):19-21. PubMed ID: 6765930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endocrine therapy for benign prostatic hyperplasia in the 90's.
    Ekman P
    J Urol (Paris); 1995; 101(1):22-5. PubMed ID: 7545721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aromatase inhibition in the dog. II. Effect on growth, function, and pathology of the prostate.
    Oesterling JE; Juniewicz PE; Walters JR; Strandberg JD; Steele RE; Ewing LL; Coffey DS
    J Urol; 1988 Apr; 139(4):832-9. PubMed ID: 2451040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.